Can-Fite BioPharma Future Growth

Future criteria checks 0/6

Can-Fite BioPharma's earnings are forecast to decline at 3.5% per annum while its annual revenue is expected to grow at 2.2% per year.

Key information

-3.5%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	36.9%
Revenue growth rate	2.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

TASE:CANF - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1	-8	N/A	N/A	1
12/31/2025	1	-7	N/A	N/A	1
12/31/2024	1	-7	N/A	N/A	1
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-9	N/A	N/A	N/A
6/30/2023	1	-10	-10	-10	N/A
3/31/2023	1	-10	N/A	N/A	N/A
12/31/2022	1	-10	-11	-11	N/A
9/30/2022	1	-14	N/A	N/A	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-16	N/A	N/A	N/A
12/31/2021	1	-15	-10	-10	N/A
9/30/2021	1	-12	N/A	N/A	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	N/A	N/A	N/A
12/31/2020	1	-15	-12	-12	N/A
9/30/2020	1	-13	N/A	N/A	N/A
6/30/2020	2	-17	-14	-14	N/A
3/31/2020	2	-13	N/A	N/A	N/A
12/31/2019	2	-13	-11	-11	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	N/A	N/A	N/A
12/31/2018	4	-7	-4	-4	N/A
9/30/2018	4	-5	N/A	N/A	N/A
6/30/2018	2	-6	-5	-5	N/A
3/31/2018	1	-5	N/A	N/A	N/A
12/31/2017	1	-6	-9	-9	N/A
9/30/2017	1	-6	N/A	N/A	N/A
6/30/2017	0	-9	N/A	-9	N/A
3/31/2017	0	-7	N/A	N/A	N/A
12/31/2016	0	-8	N/A	-9	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-6	N/A	-8	N/A
3/31/2016	0	-6	N/A	N/A	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-7	N/A	N/A	N/A
6/30/2015	0	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	-7	N/A
9/30/2014	N/A	-7	N/A	N/A	N/A
6/30/2014	N/A	-8	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	N/A	N/A
12/31/2013	N/A	-8	N/A	-9	N/A
9/30/2013	N/A	-7	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CANF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CANF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CANF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CANF's revenue (2.2% per year) is forecast to grow slower than the IL market (3.7% per year).

High Growth Revenue: CANF's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CANF's Return on Equity is forecast to be high in 3 years time

Can-Fite BioPharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

First quarter 2021 earnings released: US$0.004 loss per share (vs US$0.025 loss in 1Q 2020)

No longer forecast to breakeven

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study

Full year 2020 earnings released: US$0.04 loss per share (vs US$0.11 loss in FY 2019)

Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study